AI医疗兴起前夜，硅谷远程医疗惊现巨大丑闻，引发信任危机与监管加码

Core Viewpoint - The article highlights a significant scandal in the telemedicine sector, particularly involving Done Global, which has been accused of illegal drug distribution and fraudulent practices, raising concerns about ethics and safety in the healthcare industry [2][6]. Group 1: Company Overview - Done Global, founded by Ruthia He, rapidly expanded during the COVID-19 pandemic by offering online ADHD diagnosis and Adderall prescription services, capitalizing on relaxed telemedicine regulations [3][4]. - The company charged patients a subscription fee of $79 per month for online assessments and prescriptions, making it easy for users to access controlled substances [3]. Group 2: Legal Issues and Allegations - Ruthia He and David Brody were found guilty of illegal distribution of Adderall and submitting fraudulent claims, with the case involving over $100 million [2][4]. - The company employed aggressive marketing strategies, misleading potential patients about their need for ADHD treatment, and pressured doctors to limit consultation times to 30 minutes [4][5]. Group 3: Financial and Operational Practices - Done Global's revenue exceeded $100 million, with practices such as automatic prescription renewals and submitting false claims to insurance companies, resulting in over $14 million in fraud [5]. - The company faced severe consequences, including patient harm due to easy access to medications, which contributed to a nationwide shortage of Adderall [6]. Group 4: Regulatory Implications - The case has prompted a call for stricter regulations in the telemedicine sector, particularly regarding the prescription of controlled substances, with potential increases in compliance requirements [6]. - The U.S. Department of Justice indicated that this case marks the beginning of ongoing efforts to combat illegal drug distribution in the digital health space [6].